Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)

Haematologica

Volumn 93, Issue 9, 2008, Pages 1426-1428

  Zenhäusern, Reinhard ^a,g   Simcock, Mathew ^b   Gratwohl, Alois ^c   Hess, Urs ^d   Bargetzi, Mario ^e   Tobler, Andreas ^f  

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f Inselspital Berrn

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Hairy cell leukemia; Relapse; Rituximab

Indexed keywords

ALPHA INTERFERON; CD103 ANTIGEN; CLADRIBINE; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; RITUXIMAB; SAKK 31 98; UNCLASSIFIED DRUG;

DRUG EFFICACY; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; LETTER; RECURRENT DISEASE; RISK FACTOR; SPLENECTOMY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, HAIRY CELL; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 50849088318     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11564     Document Type: Letter

References (10)

1. Cawley JC. Hairy-cell leukaemia: Biology and management. Br J Hematol 1999;106:2-8.
2. Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H, et al. Advances in the treatment of hairy-cell Leukaemia. Lancet Oncol 2003;4:86-94.
3. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138-42.
4. Saven A, Burian C, Koziol A, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26.
5. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-6.
6. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Pathol 1998;51:364-9.
7. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115:609-11.
8. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Haematologica 2001;86:1046-50.
9. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-3.
10. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al. Rituximab in relapsed or refractory hairy cell leukaemia. Blood 2003;102:3906-11.